9-ethyl-9H-carbazole-3-carbaldehyde oxime

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 9-ethyl-9H-carbazole-3-carbaldehyde oxime
• 英文别名: (NE)-N-[(9-ethylcarbazol-3-yl)methylidene]hydroxylamine
• 化学式: C₁₅H₁₄N₂O
• 分子量: 238.28
• InChiKey: FTCBKTWYMQRPFV-MHWRWJLKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  37.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  9-ethyl-9H-carbazole-3-carbaldehyde oxime 、 盐酸 生成 N-[(9-ethylcarbazol-3-yl)methyl]hydroxylamine
  参考文献：
  名称：

  SUMMERS, JAMES B.

  摘要：

  DOI：
• 作为产物：
  描述：

  N-乙基咔唑-3-甲醛 、 Hydroxyazanium;chloride 、 吡啶 、 乙醇 生成 9-ethyl-9H-carbazole-3-carbaldehyde oxime
  参考文献：
  名称：

  SUMMERS, JAMES B.

  摘要：

  DOI：

文献信息

• Tricyclic lipoxygenase inhibiting compounds
  申请人：ABBOTT LABORATORIES

  公开号：EP0346939A1

  公开（公告）日：1989-12-20

  Compounds of the formula: wherein R1 is hydrogen, C1 to C4 alkyl, C2 to C4 alkenyl, or NR2R3, wherein R2 and R3 are independently selected from hydrogen, C1 to C4 alkyl and hydroxyl, but R2 and R3 are not simultanecusly hydroxyl; X is oxygen, sulfur, SO2, or NR4, wherein R4 is hydrogen, C1 to C6 alkyl, C1 to C6 alkoyl or aroyl; A is selected from C1 to C6 alkylene and C2 to C6 alkenylene; Y is selected independently at each occurrence from hydrogen, halogen, hydroxy, cyano, nitro, halosubstituted alkyl, C1 to C12 alkyl, C2 to C12 alkenyl, C1 to C12 alkoxy, C3 to C8 cycloalkyl, aryl, aryloxy, aroyl, C1 to C12 arylalkyl, C2 to C12 arylalkenyl, C1 to C12 arylalkoxy, C1 to C12 arylthioalkoxy, and substituted derivatives of aryl, aryloxy, aroyl, C1 to C12 arylalkyl, C2 to C12 arylalkenyl, C1 to C12 arylalkoxy, or C1 to C12 arylthioalkoxy, wherein C12 alkyl, alkoxy, and halosubstituted alkyl; n is a number having the values 0-4; when n = 0 then Y = hydrogen; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C1 to C12 alkoyl. These compounds are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method of inhibiting lipoxygenase.

  式中的化合物： 其中 R1 是氢、C1 至 C4 烷基、C2 至 C4 烯基或 NR2R3，其中 R2 和 R3 独立选自氢、C1 至 C4 烷基和羟基，但 R2 和 R3 不同时是羟基； X 是氧、硫、SO2 或 NR4，其中 R4 是氢、C1 至 C6 烷基、C1 至 C6 烷酰基或芳基； A 选自 C1 至 C6 亚烷基和 C2 至 C6 烯基； C1 至 C12 芳烷氧基、C1 至 C12 芳硫基烷氧基，以及芳基、芳氧基、芳烷基、C1 至 C12 芳烷基、C2 至 C12 芳烯基、C1 至 C12 芳烷氧基或 C1 至 C12 芳硫基烷氧基的取代衍生物，其中 C12 烷基、烷氧基和卤代烷基；n 是数值为 0-4 的数字；当 n = 0 时，Y = 氢； M 是氢、药学上可接受的阳离子、芳基或 C1 至 C12 烷酰基。这些化合物是 5-和/或 12-脂氧合酶的强效抑制剂。还公开了抑制脂氧合酶的组合物和抑制脂氧合酶的方法。
• TRICYCLIC LIPOXYGENASE INHIBITING COMPOUNDS, COMPOSITIONS, METHODS OF USE
  申请人：ABBOTT LABORATORIES

  公开号：EP0422079A1

  公开（公告）日：1991-04-17
• EP0422079A4
  申请人：——

  公开号：EP0422079A4

  公开（公告）日：1991-08-21
• US4822811A
  申请人：——

  公开号：US4822811A

  公开（公告）日：1989-04-18
• [EN] TRICYCLIC LIPOXYGENASE INHIBITING COMPOUNDS, COMPOSITIONS, METHODS OF USE
  申请人：ABBOTT LABORATORIES

  公开号：WO1989012636A1

  公开（公告）日：1989-12-28

  (EN) Compounds of formula (I), wherein R1 is hydrogen, C1 to C4 alkyl, C2 to C4 alkenyl, or NR2R3, wherein R2 and R3 are independently selected from hydrogen, C1 to C4 alkyl and hydroxyl, but R2 and R3 are not simultaneously hydroxyl; X is oxygen, sulfur, SO2, or NR4, wherein R4 is hydrogen, C1 to C6 alkyl, C1 to C6 alkoyl or aroyl; A is selected from C1 to C6 alkylene and C2 to C6 alkenylene; Y is selected independently at each occurrence from hydrogen, halogen, hydroxy, cyano, nitro, halosubstituted alkyl, C1 to C12 alkyl, C2 to C12 alkenyl, C1 to C12 alkoxy, C3 to C8 cycloalkyl, aryl, aryloxy, aroyl, C1 to C12 arylalkyl, C2 to C12 arylalkenyl, C1 to C12 arylalkoxy, C1 to C12 arylthioalkoxy, and substituted derivatives of aryl, aryloxy, aroyl, C1 to C12 arylalkyl, C2 to C12 arylalkenyl, C1 to C12 arylalkoxy, or C1 to C12 arylthioalkoxy, wherein substituents are independently selected from halo, nitro, cyano, C1 to C12 alkyl, alkoxy, and halosubstituted alkyl; n is a number having the values 0-4; when n = 0 then Y = hydrogen; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C1 to C12 alkoyl. These compounds are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method of inhibiting lipoxygenase.(FR) Composés selon la formule (I), où R1 est hydrogène, C1 à C4 alkyle, C2 à C4 alkenyle, ou NR2R3, où R2 et R3 sont choisis, indépendamment l'un de l'autre, parmi hydrogène, C1 à C4 alkyle et hydroxyle, mais R2 et R3 ne sont pas simultanément hydroxyle; X est oxygène, soufre, SO2, ou NR4, où R4 est hydrogène, C1 à C6 alkyle, C1 à C6 alkoyle ou aroyle; A est choisi parmi C1 à C6 alkylène et C2 à C6 alkenylène; Y est choisi, indépendamment chaque fois, parmi hydrogène, halogène, hydroxy, cyano, nitro, alkyle halo-substitué, C1 à C12 alkyle, C2 à C12 alkenyle, C1 à C12 alkoxy, C3 à C8 cycloalkyle, aryle, aryloxy, aroyle, C1 à C12 arylalkyle, C2 à C12 arylalkenyle, C2 à C12 arylalkoxy, C1 à C12 arylthioalkoxy, et des dérivés substitués d'aryle, aryloxy, aroyle, C1 à C12 arylalkyle, C2 à C12 arylalkenyle, C1 à C12 arylalkoxy, ou C1 à C12 arylthioalkoxy, où les substituants sont choisis, indépendamment les uns des autres, parmi halo, nitro, cyano, C12 alkyle, alkoxy, et alkyl halo-substitué; n est un nombre compris entre 0 et 4; lorsque n = 0, alors Y = hydrogène; et M est hydrogène, un cation pharmaceutiquement acceptable, aroyle, ou C1 à C12 alkoyle. Lesdits composés sont des inhibiteurs puissants des enzymes 5-lipoxygénase et/ou 12-lipoxygénase. L'invention porte également sur des compositions inhibitrices de lipoxygénase et sur une méthode d'inhibition de lipoxygénase.